Thirty-Five Years of Intravesical Bacillus Calmette-Guerin for Bladder Cancer: Where Now?

被引：2
作者：
Catto, James W. F. [1 ,2 ]
机构：
[1] Univ Sheffield, Sch Med, Inst Canc Studies, Sheffield S10 2RX, S Yorkshire, England
[2] Univ Sheffield, Sch Med, Acad Urol Unit, Sheffield S10 2RX, S Yorkshire, England
来源：
EUROPEAN UROLOGY | 2011年 / 60卷 / 01期
关键词：
TRANSITIONAL-CELL CARCINOMA; T1; TA; IMMUNOTHERAPY; METAANALYSIS; PROGRESSION; RECURRENCE; RISK;
D O I：
10.1016/j.eururo.2011.04.024
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：37 / 38
页数：2
相关论文
共 10 条
[1]   EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder, the 2011 Update [J].
Babjuk, Marko ;
Oosterlinck, Willem ;
Sylvester, Richard ;
Kaasinen, Eero ;
Boehle, Andreas ;
Palou-Redorta, Juan ;
Roupret, Morgan .
EUROPEAN UROLOGY, 2011, 59 (06) :997-1008
[2]   Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies [J].
Brausi, M ;
Collette, L ;
Kurth, K ;
van der Meijden, AP ;
Oosterlinck, W ;
Witjes, JA ;
Newling, D ;
Bouffioux, C ;
Sylvester, RJ .
EUROPEAN UROLOGY, 2002, 41 (05) :523-530
[3]   The Role of Bacillus Calmette-Guerin in the Treatment of Non-Muscle-Invasive Bladder Cancer [J].
Gontero, Paolo ;
Bohle, Andreas ;
Malmstrom, Per-Uno ;
O'Donnell, Michael A. ;
Oderda, Marco ;
Sylvester, Richard ;
Witjes, Fred .
EUROPEAN UROLOGY, 2010, 57 (03) :410-429
[4]   Bacillus Calmette-Guerin Without Maintenance Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer [J].
Herr, Harry W. ;
Dalbagni, Guido ;
Donat, Sherri M. .
EUROPEAN UROLOGY, 2011, 60 (01) :32-36
[5]   An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously T1G3) Bladder Cancer [J].
Kulkarni, Girish S. ;
Hakenberg, Oliver W. ;
Gschwend, Juergen E. ;
Thalmann, George ;
Kassouf, Wassim ;
Kamat, Ashish ;
Zlotta, Alexandre .
EUROPEAN UROLOGY, 2010, 57 (01) :60-70
[6]   A RANDOMIZED TRIAL OF INTRAVESICAL DOXORUBICIN AND IMMUNOTHERAPY WITH BACILLE CALMETTE-GUERIN FOR TRANSITIONAL-CELL CARCINOMA OF THE BLADDER [J].
LAMM, DL ;
BLUMENSTEIN, BA ;
CRAWFORD, ED ;
MONTIE, JE ;
SCARDINO, P ;
GROSSMAN, HB ;
STANISIC, TH ;
SMITH, JA ;
SULLIVAN, J ;
SAROSDY, MF ;
CRISSMAN, JD ;
COLTMAN, CA .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (17) :1205-1209
[7]   Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study [J].
Lamm, DL ;
Blumenstein, BA ;
Crissman, JD ;
Montie, JE ;
Gottesman, JE ;
Lowe, BA ;
Sarosdy, MF ;
Bohl, RD ;
Grossman, HB ;
Beck, TM ;
Leimert, JT ;
Crawford, ED .
JOURNAL OF UROLOGY, 2000, 163 (04) :1124-1129
[8]   An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guerin for Non-Muscle-Invasive Bladder Cancer [J].
Malmstrom, Per-Uno ;
Sylvester, Richard J. ;
Crawford, David E. ;
Friedrich, Martin ;
Krege, Susanne ;
Rintala, Erkki ;
Solsona, Eduardo ;
Di Stasi, Savino M. ;
Witjes, J. Alfred .
EUROPEAN UROLOGY, 2009, 56 (02) :247-256
[9]   Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials [J].
Sylvester, RJ ;
van der Meijden, APM ;
Lamm, DL .
JOURNAL OF UROLOGY, 2002, 168 (05) :1964-1970
[10]   Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials [J].
Sylvester, RJ ;
van der Meijden, APM ;
Oosterlinck, W ;
Witjes, JA ;
Bouffioux, C ;
Denis, L ;
Newling, DWW ;
Kurth, K .
EUROPEAN UROLOGY, 2006, 49 (03) :466-477
1